TAAR8C inhibitors are a class of chemical compounds that specifically target and inhibit the activity of TAAR8C, a member of the trace amine-associated receptor (TAAR) family. TAARs are a subset of G-protein-coupled receptors (GPCRs) that respond to trace amines, which are structurally similar to classical biogenic amines like dopamine, serotonin, and histamine. TAAR8C, in particular, is expressed in certain tissues and is believed to play a role in modulating cellular responses to specific environmental or endogenous ligands. Inhibitors of TAAR8C work by blocking the receptor's ability to bind its natural ligands or by interfering with the signaling pathways activated upon ligand binding. This inhibition can disrupt the receptor's role in modulating intracellular signaling cascades, which are often linked to broader physiological processes such as sensory perception or metabolic regulation.
The study of TAAR8C inhibitors is essential for understanding the specific role of this receptor within the broader TAAR family and how it contributes to cellular communication and response. By inhibiting TAAR8C, researchers can explore how blocking this receptor affects signal transduction, particularly in pathways involving cAMP (cyclic adenosine monophosphate) or other second messengers that are typically activated by GPCRs. This research provides insights into the regulatory functions of TAAR8C in response to trace amines, as well as how its inhibition alters cellular responses to changes in the chemical environment. Furthermore, TAAR8C inhibitors help scientists elucidate the interactions between TAAR receptors and other cellular signaling mechanisms, offering a deeper understanding of the complex networks that regulate cellular behavior and adaptation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine may inhibit trace amine-associated receptor 8C expression by acting as an antagonist at α2-adrenergic receptors, which could interfere with the receptor's signaling cascade. | ||||||
Reserpine | 50-55-5 | sc-203370 sc-203370A | 1 g 5 g | $137.00 $414.00 | 1 | |
Reserpine may inhibit trace amine-associated receptor 8C expression by depleting stores of monoamine neurotransmitters, potentially disrupting the signaling pathways involved in receptor expression. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol may inhibit trace amine-associated receptor 8C expression by antagonizing β-adrenergic receptors, which could interfere with downstream signaling cascades regulating receptor expression. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine may inhibit trace amine-associated receptor 8C expression by inhibiting serotonin reuptake, potentially altering serotonin levels and downstream signaling pathways that regulate receptor expression. | ||||||
1-Adamantylamine | 768-94-5 | sc-251475 sc-251475A | 1 g 25 g | $39.00 $147.00 | ||
Amantadine may inhibit trace amine-associated receptor 8C expression by modulating dopamine release and reuptake, affecting downstream signaling pathways involved in receptor expression. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol may inhibit trace amine-associated receptor 8C expression by antagonizing dopamine receptors, which could disrupt downstream signaling cascades involved in regulating receptor expression. | ||||||
Imipramine | 50-49-7 | sc-507545 | 5 mg | $190.00 | ||
Imipramine may inhibit trace amine-associated receptor 8C expression by inhibiting the reuptake of norepinephrine and serotonin, potentially altering levels of these neurotransmitters and downstream pathways regulating receptor expression. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
Chlorpromazine may inhibit trace amine-associated receptor 8C expression by antagonizing dopamine receptors and interfering with dopamine release, potentially disrupting downstream signaling pathways involved in receptor expression. | ||||||